Synjardy 12.5 mg/1

Synjardy 12.5 mg/1 tablets combine empagliflozin and metformin hydrochloride for managing type 2 diabetes. This oral medication supports blood sugar control as part of a broader treatment plan.

Synjardy 12.5 mg/1 tablets are used to improve glycemic control in adults with type 2 diabetes. This combination medication works by enhancing the body's response to insulin and reducing glucose absorption in the kidneys. It is typically prescribed alongside diet and exercise to manage blood sugar levels effectively.

Common effects of Synjardy 12.5 mg/1 tablets may include urinary tract infections, nausea, and diarrhea. Some users might experience low blood sugar, especially when combined with other diabetes medications. It's important to monitor blood sugar levels regularly while using this medication.

Synjardy 12.5 mg/1 tablets should be used with caution in individuals with kidney problems or a history of lactic acidosis. It is essential to stay hydrated and avoid excessive alcohol consumption while taking this medication. Always consult a healthcare provider before starting or stopping any medication.

Synjardy 12.5 mg/1 tablets may interact with certain medications, including other diabetes drugs, diuretics, and some antibiotics. Alcohol and certain pain medications can also affect the efficacy and safety of this medication. Always inform your healthcare provider about all medications you are taking.